What is the recommended dosage of Pradaxa for patients with CrCl>30?

What is the recommended dosage of Pradaxa for patients with CrCl>30?

• A. 75 mg orally BID
• B. 150 mg orally BID
• C. 300 mg orally BID
• D. 100 mg orally BID

Answer: (B)

The recommended dosage of Pradaxa (dabigatran etexilate) for patients with a creatinine clearance (CrCl) greater than 30 mL/min is 150 mg orally twice daily (BID). This dosage is supported by clinical guidelines that indicate this dosing for individuals who do not have any contraindications, such as severe renal impairment or specific drug interactions. When renal function is reasonably preserved, indicated by a CrCl greater than 30 mL/min, the higher dosage of 150 mg BID provides effective anticoagulation while maintaining an acceptable safety profile. This is critical for preventing thromboembolic events, particularly in patients with conditions like atrial fibrillation or those at risk for venous thromboembolism. Thus, selecting 150 mg BID reflects adherence to established recommendations for patients who can tolerate higher doses without increased risk.

The recommended dosage of Pradaxa (dabigatran etexilate) for patients with a creatinine clearance (CrCl) greater than 30 mL/min is 150 mg orally twice daily (BID). This dosage is supported by clinical guidelines that indicate this dosing for individuals who do not have any contraindications, such as severe renal impairment or specific drug interactions.

When renal function is reasonably preserved, indicated by a CrCl greater than 30 mL/min, the higher dosage of 150 mg BID provides effective anticoagulation while maintaining an acceptable safety profile. This is critical for preventing thromboembolic events, particularly in patients with conditions like atrial fibrillation or those at risk for venous thromboembolism.

Thus, selecting 150 mg BID reflects adherence to established recommendations for patients who can tolerate higher doses without increased risk.